Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on Aug. 15)
- Novocure Ltd (NASDAQ: NVCR)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Aug. 15)
- AbbVie Inc (NYSE: ABBV)
- Acer Therapeutics Inc (NASDAQ: ACER)
- Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP)
- Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
- Aldeyra Therapeutics Inc (NASDAQ: ALDX)
- Amneal Pharmaceuticals Inc (NYSE: AMRX)
- Alector Inc (NASDAQ: ALEC)
- ANCHIANO THERAP/S ADR (NASDAQ: ANCN)
- Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
- BioTelemetry Inc (NASDAQ: BEAT)
- Cellectis SA (NASDAQ: CLLS)
- Cyclerion Therapeutics Inc (NASDAQ: CYCN)
- DelMar Pharmaceuticals Inc (NASDAQ: DMPI)(announced pricing of its $6.5 million common stock offering at $1 per share)
- Eton Pharmaceuticals Inc (NASDAQ: ETON)
- Fulcrum Therapeutics Inc (NASDAQ: FULC)
- Gemphire Therapeutics Inc (NASDAQ: GEMP)
- Genetic Technologies Limited (NASDAQ: GENE)
- GENFIT S A/ADR (NASDAQ: GNFT)
- HTG Molecular Diagnostics Inc (NASDAQ: HTGM)
- Idera Pharmaceuticals Inc (NASDAQ: IDRA)
- Innovate Biopharmaceuticals Inc (NASDAQ: INNT)
- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
- Jaguar Health Inc (NASDAQ: JAGX)(reacted to its second-quarter results)
- Kala Pharmaceuticals Inc (NASDAQ: KALA)
- Kiniksa Pharmaceuticals Ltd ((NASDAQ: KNSA)
- Mallinckrodt PLC (NYSE: MNK)(fell despite reporting positive results for its drug to treat hepatorenal syndrome 1)
- MEI Pharma Inc (NASDAQ: MEIP)
- Medigus ADR (NASDAQ: MDGS)
- Meridian Bioscience, Inc. (NASDAQ: VIVO)
- Mersana Therapeutics Inc (NASDAQ: MRSN)
- MOTIF BIO PLC/S ADR (NASDAQ: MTFB)
- Neuralstem, Inc. (NASDAQ: CUR)(reacted to second-quarter results)
- Nuvectra Corp (NASDAQ: NVTR)
- Organogenesis Holdings Inc (NASDAQ: ORGO)
- Pluristem Therapeutics Inc. (NASDAQ: PSTI)
- Plus Therapeutics Inc (NASDAQ: PSTV)
- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)
- Prothena Corporation PLC (NASDAQ: PRTA)
- Regenxbio Inc (NASDAQ: RGNX)
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)
- Rubius Therapeutics Inc (NASDAQ: RUBY)
- Savara Inc (NASDAQ: SVRA)
- Supernus Pharmaceuticals Inc (NASDAQ: SUPN)
- Synlogic Inc (NASDAQ: SYBX)
- Synthetic Biologics Inc (NYSE: SYN)
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA)
- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (reported below-consensus earnings for the second quarter)
- Trevi Therapeutics Inc (NASDAQ: TRVI)
- Unity Biotechnology Inc (NASDAQ: UBX)
- Viking Therapeutics Inc (NASDAQ: VKTX)
- Xenetic Biosciences Inc (NASDAQ: XBIO)(reacted to second-quarter results)
Stocks In Focus Nabriva To Resubmit Contepo NDA In Q4
Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) announced, following the receipt of the final minutes of a Type A meeting it had with the FDA, it expects to resubmit the NDA for Contepo injection for treating complicated urinary tract infections, including acute pyelonephritis, early in the fourth quarter of 2019.
The Type A meeting was convened to resolve the issues identified in the complete response letter to the originally submitted NDA, which related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers. The FDA had not sought any additional clinical or non-clinical data.
The stock was seen rising 4.17% to $2.25 in pre-market trading Friday.
Roche Gets Nod For Its Personalized Cancer Medicine In Two Indications
Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the FDA approved its entrectinib – brand name Rozlytrek – for the treatment of adults with ROS1-positive metastatic non-small cell lung cancer.
The regulatory agency has also granted accelerated approval for entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase, or NTRK, gene fusion without a known acquired resistance mutation.
"Rozlytrek's FDA approval for two rare types of cancer is an important advance for patients, combining a targeted medicine and genomic testing to bring this new treatment option to patients who are waiting," said Sandra Horning, Roche's Chief Medical Officer.
Bellicum To Offer Preferred Stock and Warrants To Raise Gross Proceeds Of $53M
Bellicum said it would offer shares of its Series 1 preferred stock and warrants to purchase shares of its common stock in a public offering to raise gross proceeds of about $53 million.
Each share of Series 1 preferred stock is being sold together with one warrant to purchase 100 shares of common stock at a combined price to the public.
Th company also announced a concurrent private placement for raising $70 million.
The stock fell 5.01% to 95 cents in after-hours trading.
Masimo Makes Strategic Investment In Germany's TNI medical
Masimo Corporation (NASDAQ: MASI) said it has closed a strategic investment with TNI medical AG, a privately-held commercial-stage medical device company based in Germany.
"TNI's novel softFlow technology is designed to provide high flow, warmed and humidified respiratory gases to spontaneously breathing patients suffering from pulmonary disease," Masimo said.
Plus Therapeutics reported second-quarter contract revenues of $0.3 million in 2019, down from the $0.9 million revenues in 2018. The net loss per share from continuing operations narrowed from $18.53 to $5.12. The company ended the quarter with cash and cash equivalents of $4.5 million.
The stock soared 15.98% to $4.50 in after-hours trading.
See more from Benzinga
- The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings
- The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
- Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.